Skip to main content
SpringerLink
Log in

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

  • Clinical Investigations
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Bisphosphonates are potent inhibitors of osteoclastic activity and reduce the disease-related skeletal complications when they are used in combination with chemotherapy in patients with multiple myeloma (MM). Pamidronate also inhibits apoptosis of primary osteoblastic cells and probably induces apoptosis on human MM cells and osteoclasts. It has been reported that interferon-alpha (IFN-α) decreases bone resorption and that low doses of IFN-α result in a significant increase in serum osteocalcin (OSC). The aim of this study was to determine the effects of pamidronate treatment on biochemical markers of bone resorption [cross-linked N-telopeptides of type I collagen (NTx)], bone formation [bone alkaline phosphatase (BAP) and OSC], disease activity [β2-microglobubin, CRP, paraprotein], and interleukin-6 (IL-6) in patients with MM in plateau phase under IFN-α maintenance. The above parameters were evaluated in 28 patients (13 M, 15 F, median age 70 years) during maintenance treatment, before the addition of pamidronate and after 1, 3, 6, 9, 12, and 14 months of the combined therapy. The addition of pamidronate to maintenance treatment resulted in a significant reduction of NTx, IL-6, β2-microglobulin, CRP from the 3rd month and para-protein from the 6th month of treatment, whereas BAP and OSC were significantly increased from the 6th month. These changes continued during the 14-month follow-up of the combined treatment. Multivariate analysis showed a significant negative correlation between changes of BAP and OSC and the patients' age. The greater increase of the bone for-mation markers was observed in younger patients. These results suggest that, in addition to the inhibition of osteoclastic activity, pamidronate in combination with IFN-α was shown to induce bone formation in patients with MM in the plateau phase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mundy GR (1998) Myeloma bone disease. Eur J Cancer 34:246–251

    Article  CAS  PubMed  Google Scholar 

  2. Anderson KC, Lust JA (1999) Role of cytokines in multiple myeloma. Semin Hematol 36 (suppl 31):14–20

    CAS  PubMed  Google Scholar 

  3. Suda T, Nakamura I, Jimi E, Takahashi N (1997) Regulation of osteoclast function. J Bone Miner Res 12:869–879

    Article  CAS  PubMed  Google Scholar 

  4. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin Oncol 9:1397–1402

    CAS  PubMed  Google Scholar 

  5. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992) Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340:1049–1052

    Article  CAS  PubMed  Google Scholar 

  6. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone FJ, Reitsma DJ, Heffernar M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488–493

    Article  CAS  PubMed  Google Scholar 

  7. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MCR Working Party on Leukaemia in Adults. Br J Haematol 100:317–325

    Article  CAS  PubMed  Google Scholar 

  8. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J, Kandra A (1998) Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish cooperative study group. Br J Haematol 101:280–286

    Article  CAS  PubMed  Google Scholar 

  9. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone FJ, Reitsma DJ, Heffernar M, Seaman J, Knight RD, Myeloma Aredia Study Group (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16:593–602

    CAS  PubMed  Google Scholar 

  10. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220–229

    Article  CAS  PubMed  Google Scholar 

  11. Ludwig H, Cohen AM, Polliack A, Huber H, Nachbaur D, Senn HJ, Morant R, Eckhardt S, Gunczler P, Seewann SL, Schuller J, Rhyner K, Cavalli F, Fritz E (1995) Interferonalpha for induction and maintenance in multiple myeloma: results of two multicentre randomized trials and summary of other studies. Ann Oncol 6:467–476

    CAS  PubMed  Google Scholar 

  12. Fritz E, Ludwig H (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11:1427–1436

    Article  CAS  PubMed  Google Scholar 

  13. Goodman GR, Dissanayake IR, Gorodetsky E, Zhou H, Ma YE, Jee WS, Epstein S (1999) Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat. Bone 25:459–463

    Article  CAS  PubMed  Google Scholar 

  14. Withold W (1996) Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. Eur J Clin Chem Clin Biochem 34:785–799

    CAS  PubMed  Google Scholar 

  15. Schneider DL, Barrett-Connor EL (1997) Urinary N-telopeptide levels discriminate normal osteopenic and osteoporotic bone mineral density. Arch Intern Med 157:1241–1245

    Article  CAS  PubMed  Google Scholar 

  16. Withold W, Friedrich W, Reinauer H (1996) Comparison of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases. Ann Clin Biochem 33:421–427

    CAS  PubMed  Google Scholar 

  17. Chronic Leukaemia-Myeloma Task Force: National Cancer Institute Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 4:145–158

  18. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34:2021–2026

    Article  CAS  PubMed  Google Scholar 

  19. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL (1998) Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 63:363–368

    Article  CAS  PubMed  Google Scholar 

  20. Tsuda-Futami E, Shioi A, Jono S, Inaba M, Nishizawa Y, Morii H (1998) Lymp0hoblastoid interferon-alpha downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor expression in human osteoblastic cells (Saos-2). Bone 23:205–211

    Article  CAS  PubMed  Google Scholar 

  21. Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229–1241

    Article  CAS  PubMed  Google Scholar 

  22. Linkhart TA, Linkhart SG, McCharles DC, Long DL, Strong DD (1991) Interleukin-6-messager, RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: regulation by interleukin-1. J Bone Miner Res 6:1285–1294

    Article  CAS  PubMed  Google Scholar 

  23. Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R, Roodman GD (1992) Evidence for an autocrine/ paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 131:2229–2234

    Article  CAS  PubMed  Google Scholar 

  24. Klein B, Zhang XG, Lu ZY, Bataille R (1995) Interleukin-6 in human multiple myeloma. Blood 85:863–872

    CAS  PubMed  Google Scholar 

  25. Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3–21

    CAS  PubMed  Google Scholar 

  26. Kunzmann V, Bauer E, Feurle J, Weibinger F, Tony HP, Wilhelm M (2000) Stimulation of y δ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392

    CAS  PubMed  Google Scholar 

  27. Minami R, Muta K, Ilseung C, Abe Y, Nishimura J, Nawata H (2000) Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha. Exp Hematol 28:244–255

    Article  CAS  PubMed  Google Scholar 

  28. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, Meletis J, Yataganas X (2000) Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 65:331–336

    Article  CAS  PubMed  Google Scholar 

  29. Savage AD, Belson DJ, Vescio RA, Lichtenstein A, Berenson J (1996) Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients (abstract). Blood 88 (suppl 1):105a

    Google Scholar 

  30. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363–1374

    Article  CAS  PubMed  Google Scholar 

  31. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, Heickendorff L, Eriksen EF, Nielsen JL (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 62:128–134

    Google Scholar 

  32. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S (1999) Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD), and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/ osteocalcin ratios. Eur J Haematol 62:300–306

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, University of Athens Medical School, Laiko General Hospital, 2 Kazani str, 115-26, Athens, Greece

    E. Terpos, N. Viniou, G. Vaiopoulos, J. Meletis & X. Yataganas

  2. Department of Immunology, 251 General Airforce Hospital, Athens, Greece

    J. Palermos

Authors
  1. E. Terpos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Palermos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Viniou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Vaiopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Meletis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. Yataganas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terpos, E., Palermos, J., Viniou, N. et al. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. Calcif Tissue Int 68, 285–290 (2001). https://doi.org/10.1007/BF02390835

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02390835

Key words

Search

Navigation